特瑞普利单抗致甲状腺功能减退症1例分析

doi:10.19803/j.1672-8629.2021.07.22

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (7): 697-699.
DOI: 10.19803/j.1672-8629.2021.07.22

特瑞普利单抗致甲状腺功能减退症1例分析

赵爽, 苗秋丽^*, 宋燕青, 李悦

吉林大学第一院药学部,吉林长春130021

收稿日期:2019-12-23 出版日期:2021-07-15 发布日期:2021-07-23
通讯作者: ^*苗秋丽,女,硕士,主管药师,肿瘤临床药学。E-mail：miaoql365@163.com
作者简介:赵爽,女,硕士,主管药师,肿瘤临床药学。
基金资助:
国家重点研发计划（2016YFC1303804）

Hypothyroidism Caused by Terepril and Literature Analysis

ZHAO Shuang, MIAO Qiuli^*, SONG Yanqing, LI Yue

Department of Pharmacy, The First Hospital of Jilin University, Changchun Jilin 130021, China

Received:2019-12-23 Online:2021-07-15 Published:2021-07-23

摘要/Abstract

摘要： 目的以病例为基础分析特瑞普利单抗致甲状腺功能减退症的临床特点、危险因素及诊治方案。方法对1例应用特瑞普利单抗治疗直肠癌诱发甲状腺功能减退症的病例进行分析,并对相关文献进行归纳和总结。结果 1例 44岁男性患者因直肠癌多发转移,经过二、三线化疗肿瘤再次进展,给予特瑞普利单抗240 mg静脉滴注。患者出现FT3和FT4降低、TSH升高、给予左甲状腺素钠片12.5 μg每日1次口服,血常规提示,甲功三项值正常未见明显异常,患者未停用特瑞普利单抗治疗。结论特瑞普利单抗治疗过程中需关注患者的临床症状及影像学特征,鉴别其可能导致的免疫相关性甲状腺减退症,发生免疫相关性不良反应的患者需根据其严重程度不同予以相应的治疗手段,同时应警惕再次给药后的复发风险。

关键词: 特瑞普利单抗, 甲状腺功能减退症, 药品不良反应, 病例分析

Abstract: Objective To analyze the clinical characteristics, risk factors, diagnosis and therapeutic strategy of hypothyroidism caused by terepril monoclonal antibody based on the cases. Methods A case of hypothyroidism induced by rectal cancer treated with terepril monoclonal antibody was analyzed, and the related literature was summarized. Results In this case, a 44 year old male patient with multiple metastases of rectal cancer after two or three lines of chemotherapy was treated with terepril monoclonal antibody 240 mg intravenously. This patient presented with symptoms such as decreased levels of FT3 and FT4 and elevated levels of TSH . Left thyroxine sodium tablet was given 12.5 μg orally once a day. Blood routine showed that there was no significant abnormality in the three normal values of thyroid function. The patient did not stop the treatment of terepril monoclonal antibody. Conclusion During the treatment of terepril monoclonal antibody, we should pay attention to the clinical symptoms and imaging characteristics of the patients, identify the immune-related hypothyroidism that may be caused by terepril monoclonal antibody. The patients with immune-related adverse reactions should be given corresponding treatment according to their severity, and at the same time, we should be alert to the risk of recurrence after re administration.

Key words: terepril monoclonal antibody, hypothyroidism, adverse drug reactions, case analysis

中图分类号:

R994.1

赵爽, 苗秋丽, 宋燕青, 李悦. 特瑞普利单抗致甲状腺功能减退症1例分析[J]. 中国药物警戒, 2021, 18(7): 697-699.

ZHAO Shuang, MIAO Qiuli, SONG Yanqing, LI Yue. Hypothyroidism Caused by Terepril and Literature Analysis[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 697-699.

参考文献

[1] State Drug Administration.Terepril monoclonal antibody injection. The first domestic PD-1 antibody drug was approved for marketing[J]. Cancer Prevention and Treatment Research(肿瘤防治研究), 2019, 46(1): 103.
[2] Eigentler TK, Hassel JC, Berking C, et al.Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J]. Cancer Treat Rev, 2016, 45: 7-18.
[3] Zeng MF, Chen LL, Ye HY, et al.Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy Case report and review[J]. Medicine, 2017, 96(44): e8426.
[4] Ramos-Levi AM, Rogado J, Sanchez-Torres JM, et al.Nivolumab-induced thyroid dysfunction in patients with lung cancer[J].Endocrinol Diabetes Nutr, 2019, 66(1): 26-34.
[5] Yamauchi I, Sakane Y, Fukuda Y, et al.Clinical features of nivolumab-induced thyroiditis: a case series study[J]. Thyroid, 2017, 27(7): 894-901.
[6] Tanaka R, Fujisawa Y, Maruyama H, et al.Nivolumab-induced thyroid dysfunction[J]. Japanese Journal of Clinical Oncology: hyw036r, 2016, 46(6): 575-579.
[7] Khan U, Rizvi H, Sano D, et al.Nivolumab induced myxedema crisis[J]. J Immunother Cancer, 2017,5(1): 5-13.
[8] Tanaka R, Fujisawa Y, Maruyama H, et al.Nivolumab-induced thyroid dysfunction[J]. Jpn J Clin Oncol, 2016, 46(6): 575-579.
[9] Jiang CH, Wang L.Nivolumab-induced thyroid dysfunction[J]. pharmacoepidemiology(药物流行病学杂志), 2019, 28(9): 624-625
[10] Lin CS, Guo Z, Mo ZH.A case of hypothyroidism induced by nivolumab[J]. Journal of Central South University (Medical Edition)(中南大学学报(医学版)), 2019,44(2): 112-114.
[11] Ramos-Levi AM, Rogado J, Sanchez-Torres JM, et al.Nivolumab-induced thyroid dysfunction in patients with lung cancer[J]. Endocrinol Diabetes Nutr, 2019, 66(1): 26-34.
[12] Veldt van der AA, Lammertsma AA, Smit EF. Reduction in thyroid perfusion after bevacizumab treatment[J].Thyroid, 2013, 23(10): 1329-1330.
[13] Zheng FY, Wu Y, Rao YF, et al.The role and case analysis of NOEs rating scale in the evaluation of adverse drug reactions[J]. Chinese Journal of Pharmacy(中国药学杂志), 2012, 47(8): 650-652.
[14] Puzanov I, Diab A, Abdallah K, et al.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer ( SITC) Toxicity Mana-gement Working Group[J].J Immuno Ther Cancer, 2017, 5: 95.
[15] Meyer HJ, Hohn A, Surov A.Histogram analysis of ADC in rectal cancer: associations with different histopathological findings including expression of EGFR, Hif1-alpha, VEGF, p53, PD1, and KI67. A preliminary study[J].Oncotarget, 2018, 9(26): 18510-18517.
[16] Corsello SM, Barnabei A, Marchetti P, et al.Endocrine side effects induced by immune checkpoint inhibitors[J]. J Clin Endocrinol Metab, 2013, 98(4): 1361-1375.
[17] Zhu H, Zhou F, Jin J.Literature analysis of 56 cases of adverse reactions of rituximab[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018,15(1): 52-56.
[18] Cai J, Wei J, Ji LW. Literature analysis of tuberculosis induced by adalimumab [J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2018,15 (11): 46-49.`

特瑞普利单抗致甲状腺功能减退症1例分析

Hypothyroidism Caused by Terepril and Literature Analysis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.